FDA rejects ivonescimab lung cancer application after HARMONi overall survival miss
Posted on November 15, 2026
Summit Therapeutics has received a Complete Response Letter from the U.S. Food and Drug Administration for its Biologics License Application seeking approval of ivonescimab combined with platinum-containing chemotherapy in previously treated EGFR-mutated non-small cell lung cancer.
The FDA concluded that the application could not be approved in its current form because substantial evidence of effectiveness had not been established without a statistically significant improvement in overall survival.
Ivonescimab is an investigational bispecific antibody targeting PD-1 and VEGF.
The proposed indication covered patients with locally advanced or metastatic non-small cell lung cancer who had previously received an epidermal growth factor receptor tyrosine kinase inhibitor.
According to Summit, the FDA determined that the progression-free survival benefit demonstrated in the Phase III HARMONi study, without a statistically significant overall survival improvement, did not support a positive benefit-risk profile for approval.
HARMONi was a global, randomised, double-blind Phase III study comparing ivonescimab plus platinum-containing chemotherapy with placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC previously treated with a third-generation EGFR inhibitor.
The study had co-primary endpoints of progression-free survival and overall survival.
HARMONi met its progression-free survival endpoint, becoming the first global Phase III study of an immunotherapy-based regimen to demonstrate a statistically significant PFS improvement in this treatment setting.
However, the primary overall survival analysis showed a favourable trend without reaching statistical significance.
Summit said a post-hoc analysis incorporating longer-term follow-up of Western patients subsequently produced an overall survival hazard ratio of 0.76 in the full study population, Asian patients and Western patients.
These additional analyses did not change the FDA’s decision on the current application.
Summit noted that there are currently no FDA-approved regimens in this treatment setting that have demonstrated a statistically significant overall survival benefit.
The company also reported that the safety profile of ivonescimab plus chemotherapy was acceptable and manageable and remained consistent with previous studies.
Treatment-related adverse events led to discontinuation in 7.3% of patients receiving ivonescimab plus chemotherapy compared with 5.0% receiving chemotherapy alone.
Treatment-related adverse events resulted in death in four patients, or 1.8%, in the ivonescimab combination group and five patients, or 2.3%, in the control group.
Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics, said the company remained focused on developing additional treatment options for patients with significant unmet medical needs.
Chairman and Co-Chief Executive Officer Robert Duggan said Summit remained committed to the wider development of ivonescimab despite the Complete Response Letter.
The company continues to evaluate the therapy across several tumour types and treatment settings.
Ongoing Phase III programmes include HARMONi-3 in first-line metastatic NSCLC, with separate squamous and non-squamous cohorts, and HARMONi-7 evaluating ivonescimab monotherapy in first-line metastatic NSCLC with high PD-L1 expression.
Summit is also conducting the Phase III HARMONi-GI3 study in first-line metastatic colorectal cancer and the Phase II/III HARMONi-GU1 study combining ivonescimab with enfortumab vedotin in untreated metastatic urothelial carcinoma.
A Phase II study is additionally assessing several ivonescimab-based combinations in first-line metastatic clear cell renal cell carcinoma.
Summit has several external collaborations evaluating ivonescimab with other investigational therapies.
These include planned combinations with AstraZeneca and Daiichi Sankyo’s Datroway, AstraZeneca’s sonesitatug vedotin, Revolution Medicines’ RAS inhibitors, GSK’s risvutatug rezetecan and Arcus Biosciences’ casdatifan.
Ivonescimab is also being evaluated through cooperative group collaborations in advanced head and neck squamous cell carcinoma and biliary tract cancer.
The therapy remains investigational in Summit’s licensed territories, including the U.S. and Europe.
Ivonescimab was first approved in China in May 2024, while no PD-1 x VEGF bispecific antibody is currently approved in the U.S.
Related Topics and Keywords
Akeso, Biologics License Application, Biopharma, bispecific antibody, bla, chemotherapy, clinical trials, Complete Response Letter, CRL, egfr, FDA, HARMONi, Ivonescimab, lung cancer, non-small cell lung cancer, NSCLC, Oncology, overall survival, PD 1, pharma news, phase III, progression-free survival, regulatory affairs, Summit Therapeutics, VEGF
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















